💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Erlotinib

CHEMBL553 Phase 4 Approuvé Small molecule
Half-Life
36 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
393.4 g/mol
LogP
3.3
Phase
4

This oral targeted therapy blocks the EGFR protein that drives the growth of cancer cells in certain lung cancers and pancreatic cancers. It is most effective in patients whose tumors have specific EGFR mutations.

Masse moléculaire

393,4380 g/mol

LogP

3,30

TPSA

74,70 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Chronic Pain Hepatitis C Prostate Cancer Colorectal Cancer Leukemia

Classes de médicaments

L — L - Antineoplastic and Immunomodulating Agents

Mécanisme d'action

Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Pharmacokinetics (PK)

Half-Life 36 hours

Pharmacodynamics (PD)

Mécanisme

Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H23N3O4

                    

                    
                    

                        
HBD / HBA

                        
1 / 7

                    

                    
                    

                        
Liaisons Rotatives

                        
11

                    

                    
                    
                    

                        
Atomes Lourds

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This oral targeted therapy blocks the EGFR protein that drives the growth of cancer cells in certain lung cancers and pancreatic cancers. It is most effective in patients whose tumors have specific EGFR mutations.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Erlotinib: Half-life: 36 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Erlotinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL553.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 176870.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.